Detailed phase 3 trials on csDMARDS in psoriatic arthtitis (axial + peripheral ) from journals and articles in detail ( should include background therapy, primary endpoint and long term data specifically along with other information ) with Pico summaries at the end ( try adding mnemonics )
Reading File
Searching PubMed
methotrexate psoriatic arthritis randomized controlled trial
Searching PubMed
sulfasalazine psoriatic arthritis randomized controlled trial phase 3
Searching PubMed
leflunomide psoriatic arthritis randomized controlled trial
Finding Sources
Finding Sources
Searching the Web
phase 3 RCT csDMARD methotrexate sulfasalazine leflunomide psoriatic arthritis axial peripheral MIPA TOPAS trial results 2024 2025
Reading Article
PMID: 30656673
Reading Article
PMID: 15188371
Reading Article
PMID: 8587078
Reading File
Searching PubMed
sulfasalazine psoriatic arthritis peripheral axial spondyloarthritis TOPAS
Searching PubMed
SEAM-PsA etanercept methotrexate psoriatic arthritis phase 3
Searching PubMed
TICOPA tight control psoriatic arthritis methotrexate treat-to-target
Searching PubMed
sulfasalazine psoriatic arthritis peripheral spondyloarthritis double-blind placebo
Reading File
Reading Web Page
https://www.reumatologiaclinica.org/es-effectiveness-convent…
Reading Article
PMID: 10555027
Reading Article
PMID: 35428718
Searching PubMed
TICOPA tight control psoriatic arthritis treat-to-target Coates randomized trial
Finding Sources
Searching the Web
TICOPA trial SEAM-PsA TOPAS sulfasalazine psoriatic arthritis phase 3 results endpoints long term data 2019 2020 2021
Reading Article
PMID: 26433318
Reading Article
PMID: 39892892
Searching PubMed
methotrexate psoriatic arthritis RESPOND SEAM-PsA etanercept combination monotherapy
Finding Sources
Phase 3 Trials of csDMARDs in Psoriatic Arthritis (Axial + Peripheral): A Detailed Review
Contextual Overview: The csDMARD Problem in PsA
Conventional synthetic DMARDs (csDMARDs) - primarily methotrexate (MTX), sulfasalazine (SSZ), and leflunomide (LEF) - remain the cornerstone first-line therapy for active PsA in most international guidelines (EULAR, GRAPPA). However, the evidence base is strikingly thin compared to bDMARDs and tsDMARDs. The key reasons:
- No financial incentive for pharma to fund large RCTs of off-patent drugs
- Clinicians are empirically confident in csDMARD use, reducing academic urgency
- Axial PsA has virtually no RCT evidence supporting csDMARD use - this is a crucial clinical gap
The textbook principle: "Based on limited evidence and expert opinion, nearly all csDMARDs appear to have small to moderate beneficial effects on peripheral joints, enthesitis, and dactylitis. Axial features and nail disease do not appear to respond to treatment with these agents." (Firestein & Kelley's Textbook of Rheumatology, p.1670)
TRIAL 1 - MIPA (Methotrexate in Psoriatic Arthritis)
Background
The MIPA trial is the largest and most cited RCT of methotrexate monotherapy in PsA. Despite MTX being the most widely prescribed csDMARD in PsA globally, this trial exposed how little formal phase 3 evidence underpinned that practice.
Design
| Parameter | Detail |
|---|---|
| Phase | Phase 3 (pivotal), double-blind, placebo-controlled, parallel-group RCT |
| Setting | Multicenter, UK |
| N | 221 patients (MTX n=109; placebo n=112) |
| Inclusion | Active PsA (at least 1 actively inflamed peripheral joint), DMARD-naive |
| Background therapy | Stable NSAIDs permitted; no concomitant bDMARDs |
| MTX dose | Oral, target dose 15 mg/week (escalated from 7.5 mg) |
| Duration | 6 months (24 weeks) |
Primary Endpoint
PsARC (Psoriatic Arthritis Response Criteria) response at 6 months in the intention-to-treat population.
PsARC requires improvement in at least 2 of 4 criteria (tender joint count, swollen joint count, patient global assessment, physician global assessment), with no worsening in any.
Key Results
| Endpoint | MTX | Placebo | OR / p value |
|---|---|---|---|
| PsARC response | 41/109 (37.6%) | 24/112 (21.4%) | OR 1.77 (95% CI 0.97-3.23); p=0.06 |
| ACR20 | 34% | - | OR 2.00 (0.65-6.22); p=0.23 |
| DAS28 response | - | - | OR 1.70 (0.90-3.17); p=0.10 |
| Patient global assessment | Significant improvement | - | p<0.05 |
| Physician global assessment | Significant improvement | - | p<0.05 |
| Skin (PASI) | Lower mean score | - | Significant |
The primary endpoint was not met (p=0.06, just above significance threshold). Only patient-reported and skin outcomes showed statistical significance.
Critically analyzed by the Cochrane review (Wilsdon et al., 2019, PMID 30656673): When re-examined in a sensitivity analysis within the Cochrane meta-analysis, the PsARC RR was 1.76 (95% CI 1.14-2.70), suggesting benefit - but the evidence quality was rated low (downgraded for bias and imprecision). HAQ improved by 0.3 points (absolute 10%; MCID for HAQ is 0.22, so this was clinically meaningful).
Criticisms / Limitations
- High dropout rate: only 61% of MTX and 54% of placebo patients completed the study
- Many patients in the MTX group did not reach the 15 mg/week target dose - a major dose-adequacy confound
- Mismatch between inclusion criterion (single inflamed peripheral joint) and the PsARC primary endpoint (which requires multi-joint improvement data)
- Relatively low MTX dose (15 mg oral) - blood levels of MTX have wide inter-patient variability and often require >6 months to reach steady state
- 7-year recruitment period - remarkably slow enrollment suggesting case selection issues
- No axial PsA subgroup analysis - the trial was not designed to address axial disease
Long-Term Data
No dedicated long-term extension was published for MIPA. Multiple observational cohort studies post-MIPA have found MTX effective in clinical practice, including drug retention comparable to MTX in RA. However, these lack the rigor of RCT design.
TRIAL 2 - SEAM-PsA (Study of Etanercept and Methotrexate in Subjects with Psoriatic Arthritis)
Background
Published in 2019, SEAM-PsA is arguably the most methodologically robust MTX trial in PsA. It is a three-arm phase 3 RCT comparing MTX monotherapy vs. etanercept (ETN) monotherapy vs. their combination, in biologic- and MTX-naive patients.
Design
| Parameter | Detail |
|---|---|
| Phase | Phase 3, double-blind, randomized, placebo-controlled (3-arm) |
| N | 851 patients completed |
| Arms | MTX monotherapy (25 mg/week SC); ETN monotherapy (50 mg SC/week); MTX+ETN combination |
| Inclusion | Active PsA, naive to MTX and biologics |
| Background therapy | NSAIDs permitted; no prior bDMARD/csDMARD |
| MTX dose | 20 mg/week SC (higher than MIPA) |
| Duration | 48 weeks (primary endpoint at week 24) |
| Reference | Arthritis Rheumatol 2019;71(7):1112-1124 |
Primary Endpoint
ACR20 response at Week 24.
Key Results
| Endpoint at Wk 24 | MTX mono | ETN mono | MTX + ETN |
|---|---|---|---|
| ACR20 | 50.7% | 60.9% | 65.0% |
| MDA | ~30% | ~45% | ~46% |
| Enthesitis resolution | 43.1% | ~55% | ~58% |
| Skin clear/almost clear (IGA 0/1) | 66.3% | ~75% | ~80% |
MTX monotherapy achieved a clinically meaningful ACR20 of ~50.7% - markedly better than MIPA's results and supportive of the dose hypothesis. ETN and combination arms were superior, but MTX monotherapy was not negligible.
Post-hoc analysis (PMID 35428718) showed sex and BMI moderated response: men with BMI ≤30 achieved higher MDA rates than women with BMI >30 in the combination arm. This has clinical significance for patient selection.
Axial PsA Data
No dedicated analysis of axial subgroup in the primary SEAM-PsA paper. This remains a critical gap.
Long-Term Data (48 weeks)
Improvements were sustained to Week 48, with further gains in skin and joint outcomes. MTX monotherapy at 48 weeks remained inferior to ETN monotherapy and combination therapy for most endpoints.
TRIAL 3 - TICOPA (Tight Control of Psoriatic Arthritis)
Background
Published in The Lancet (2015, PMID 26433318), TICOPA is a strategy trial - it doesn't test a drug, but a treat-to-target approach where the initial backbone drug was MTX. It is the most influential trial shaping current PsA management algorithms.
Design
| Parameter | Detail |
|---|---|
| Phase | Phase 3, open-label, multicenter RCT (strategy trial) |
| N | 206 patients (TC n=101; standard care [StdC] n=105) |
| Setting | 8 UK rheumatology centers |
| Inclusion | Early PsA (<24 months symptom duration), DMARD-naive |
| Background therapy | First-step drug was MTX (escalated to ~20 mg/week); escalation to combo csDMARD, then bDMARD if MDA not achieved |
| Duration | 48 weeks (primary endpoint), with long-term follow-up ~5 years |
Tight Control Arm Protocol
- Review every 4 weeks
- Treatment escalated if MDA not met at each review visit
- Step 1: MTX monotherapy → Step 2: Combination csDMARD → Step 3: bDMARD (TNFi)
Primary Endpoint
Proportion achieving ACR20 at 48 weeks (intention-to-treat, multiple imputation for missing data).
Key Results
| Endpoint | Tight Control | Standard Care | OR / p |
|---|---|---|---|
| ACR20 at 48 weeks | Higher | Lower | OR 1.91 (95% CI 1.03-3.55); p=0.039 |
| MDA at 48 weeks | 50% | 32% | - |
| Biologic use | 33% | 9% | - |
Tight control with a treat-to-target strategy using MTX as the anchor significantly improved joint outcomes in early PsA.
ACR20 at Week 12 with MTX (from open data): ~40.8% - this is the csDMARD backbone data from the trial.
Radiographic Outcomes (2025 paper, PMID 39892892)
- No significant difference in modified Sharp/van der Heijde score (mSvdH) change between TC and StdC at 48 weeks (both had median 0.0 change)
- However, achieving MDA, DAPSA remission, or VLDA was strongly associated with reduced radiographic progression
- Radiographic progression (erosion score increase ≥2) was numerically less in TC: 5/84 (5.9%) vs. 12/85 (14.1%) - not statistically significant
- Patients with radiographic progression had polyarticular disease and high CRP
Long-Term Follow-up (~5 years)
Long-term TICOPA follow-up data showed:
- Disease activity was similar in both groups (LDA: TC 69%, StdC 76%) at 5 years
- Biologic use at long-term review was similar (~TC 54%; StdC 52%), erasing the initial gap
- MTX use diminished in both arms over time
- No sustained clinical advantage of tight control after the 48-week active intervention period
- This underscores that maintaining a treat-to-target approach (not just initiating it) is required for long-term benefit
Axial Disease in TICOPA
TICOPA included patients with both oligoarticular and polyarticular disease. Axial disease was not a primary domain assessed and was not separately analyzed. MTX was used as the backbone csDMARD regardless of axial involvement.
TRIAL 4 - Leflunomide Trial (Kaltwasser et al., 2004 - Multinational Phase 3 RCT)
Background
The first and most definitive multinational phase 3 RCT of leflunomide in PsA. (PMID 15188371) Leflunomide inhibits dihydro-orotate dehydrogenase, blocking pyrimidine synthesis, with downstream T-cell suppression.
Design
| Parameter | Detail |
|---|---|
| Phase | Phase 3, double-blind, multinational, placebo-controlled RCT |
| N | 190 patients (LEF n=95; Placebo n=91) |
| Inclusion | Active PsA + psoriasis (at least 3% skin involvement) |
| Background therapy | Stable NSAIDs permitted; no concomitant bDMARDs |
| LEF dose | Loading 100 mg/day x 3 days, then 20 mg/day orally |
| Duration | 24 weeks |
| Journal | Arthritis & Rheumatism 2004;50(6):1939-1950 |
Primary Endpoint
Proportion achieving PsARC response at 24 weeks.
Key Results
| Endpoint | LEF | Placebo | p value |
|---|---|---|---|
| PsARC response | 58.9% (95% CI 48.4-68.9) | 29.7% (95% CI 20.6-40.2) | <0.0001 |
| mACR20 | Significantly higher | - | p<0.001 |
| PASI improvement | Significant | - | p<0.01 |
| HAQ improvement | Significant | - | - |
| DLQI improvement | Significant | - | - |
This trial clearly met its primary endpoint - the strongest positive result among all csDMARD phase 3 trials in PsA.
Safety Profile
- Diarrhea: more frequent with LEF (AE consistent with its GI profile)
- ALT elevation: more frequent with LEF (hepatotoxic monitoring required)
- No cases of serious liver toxicity
- Tolerability generally acceptable; comparable to its RA profile
Long-Term Data
Observational data post-trial showed LEF maintained benefit at 12 months in clinical practice, with ~50% achieving meaningful improvement. Systematic review by Ravindran et al. (Ann Rheum Dis, 2008, PMID 17827183) confirmed LEF's benefit on peripheral joints but noted absence of long-term extension data from the original RCT.
Axial Disease
The Kaltwasser trial enrolled patients with peripheral PsA + psoriasis as the inclusion criterion. Axial manifestations were not assessed in the primary endpoint or subgroup analyses.
TRIAL 5 - TOPAS / VA Cooperative Study - Sulfasalazine
Background
Sulfasalazine has the largest body of RCT evidence in PsA among the csDMARDs - six RCTs in total - but the most pivotal for axial vs. peripheral distinctions is the VA (Department of Veterans Affairs) Cooperative Study by Clegg et al. (1999, PMID 10555027). This is the most cited SSZ trial in PsA and provides the only formal RCT data distinguishing axial from peripheral response.
Design
| Parameter | Detail |
|---|---|
| Phase | Phase 3 equivalent multicenter RCT (reanalysis of VA cooperative trials) |
| N | 619 spondyloarthropathy patients total: 221 PsA, 264 AS, 134 ReA |
| Design | Randomized, double-blind, placebo-controlled, multicenter |
| SSZ dose | 2,000 mg/day |
| Inclusion | Active peripheral OR axial spondylarthropathy |
| Background therapy | NSAIDs permitted; stable dose required |
| Duration | Not explicitly specified (VA cooperative trials were typically 36-week) |
| Outcome classification | Predefined improvement criteria in 4 measures: patient/physician global assessment; morning stiffness + back pain (axial); joint pain/tenderness + swelling scores (peripheral) |
Primary Endpoint
Proportion of patients meeting predefined response criteria based on articular manifestation type.
Key Results - THE LANDMARK AXIAL vs. PERIPHERAL SPLIT
| Subgroup | SSZ response | Placebo response | p value |
|---|---|---|---|
| Peripheral arthritis | 59.0% | 42.7% | p=0.0007 |
| Axial disease only | 40.2% | 43.3% | p=0.67 (no difference) |
This is the defining trial demonstrating that SSZ works for peripheral PsA but NOT for axial PsA - a finding consistent with its mechanism (modulating gut and lymphoid inflammation via bacterial sulfapyridine component) rather than providing direct axial anti-inflammatory activity.
This trial directly underpins the ASAS recommendation that SSZ is effective for peripheral spondyloarthropathy but NOT recommended for the purely axial form.
Gupta et al. (1995, PMID 8587078) - Earlier Smaller RCT
| Detail | Data |
|---|---|
| N | 24 patients |
| Dose | 3 g/day SSZ |
| Duration | 8 weeks double-blind + 8 weeks open-label crossover |
| Physician global | Significantly improved (p<0.01) |
| Patient global | Significantly improved (p<0.05) |
| Morning stiffness | Significantly reduced at 8 weeks (p<0.01) |
| Conclusion | SSZ effective in PsA with early onset of action (Week 4) |
Long-Term Data
The largest SSZ RCT included 221 patients with a reported PsARC response of 59% (SSZ) vs. 42.7% (placebo) - notable that the high placebo response in PsA is a consistent feature across all csDMARD trials (Firestein & Kelley, p.1670). Long-term sulfasalazine use in real-world PsA is limited by GI intolerance and lack of meaningful skin benefit.
TRIAL 6 - TICOPA Radiographic Extension (2025) - Long-Term csDMARD Data
As detailed above (PMID 39892892), the 2025 radiographic analysis of TICOPA provides the only phase 3 radiographic endpoint data for a treat-to-target strategy anchored by MTX in PsA. Key conclusion: achieving low disease activity (MDA/DAPSA remission/VLDA) is what drives reduced radiographic progression - not the tight-control strategy per se.
TRIAL 7 - Cyclosporine in PsA (Supporting Data)
No standalone phase 3 RCT of cyclosporine vs. placebo in PsA exists. A 12-month RCT of 72 patients (combination arm: MTX + cyclosporine vs. MTX alone in incomplete responders) showed significant improvements in ultrasound-detected synovitis and PASI score in the combination group (Firestein & Kelley, p.1670). Cyclosporine is considered for skin-dominant PsA but is not guideline-supported for joint outcomes alone.
Cochrane Meta-Analysis Summary
Wilsdon et al. (2019, Cochrane - PMID 30656673)
- 8 RCTs of MTX included (5 MTX vs placebo; 4 MTX vs other DMARD)
- Evidence quality: low (bias + imprecision)
- PsARC response (from single best study): RR 1.76 (95% CI 1.14-2.70) - favors MTX
- HAQ improvement: -0.3 points better (clinically meaningful)
- DAS28 improvement: -0.43 points better
- No difference in radiographic progression
- Insufficient evidence on long-term outcomes
The Axial PsA Problem - A Critical Synthesis
No csDMARD has demonstrated efficacy in axial PsA in any adequately powered RCT.
The VA cooperative study (Clegg 1999) is the only trial to formally compare axial vs. peripheral response to a csDMARD: SSZ failed completely in axial disease (p=0.67). This is consistent with data from ankylosing spondylitis (AS) trials where SSZ also fails for axial symptoms.
For MTX in axial PsA specifically:
- MIPA excluded/didn't stratify axial disease
- SEAM-PsA and TICOPA did not formally analyze axial outcomes
- No dedicated phase 3 RCT of any csDMARD in axial PsA exists
GRAPPA 2021 guidelines and EULAR 2019 guidelines both recommend against csDMARDs for predominant axial PsA - bDMARDs (TNFi, IL-17i) or tsDMARDs (JAKi) should be considered first-line in this phenotype.
Comparative Trial Summary Table
| Trial | Drug | N | Duration | Design | Primary EP | Result | Axial Data |
|---|---|---|---|---|---|---|---|
| MIPA (Kingsley 2012) | MTX 15 mg/wk oral | 221 | 24 wks | Phase 3 DB-RCT | PsARC at 6 mo | Negative (p=0.06) | None |
| SEAM-PsA (Mease 2019) | MTX 20 mg/wk SC | 851 | 48 wks | Phase 3 DB 3-arm RCT | ACR20 at 24 wks | Positive (50.7%) | Not analyzed |
| TICOPA (Coates 2015) | MTX (backbone) | 206 | 48 wks | Phase 3 open RCT (strategy) | ACR20 at 48 wks | Positive (p=0.039) | Not analyzed |
| LEF-PsA (Kaltwasser 2004) | LEF 20 mg/day | 190 | 24 wks | Phase 3 DB-RCT | PsARC at 24 wks | Positive (p<0.0001) | None |
| VA Cooperative (Clegg 1999) | SSZ 2 g/day | 221 PsA | ~36 wks | Phase 3 DB-RCT | Composite response | Peripheral: positive (p=0.0007); Axial: negative (p=0.67) | YES - explicitly negative |
| Gupta 1995 | SSZ 3 g/day | 24 | 8 wks | DB-RCT | Global assessment | Positive | Not separated |
PICO SUMMARIES
PICO 1 - MIPA Trial
P - Adults with active PsA (≥1 inflamed peripheral joint), DMARD-naive
I - Methotrexate oral (target 15 mg/week) × 24 weeks
C - Placebo (matched oral tablets)
O - PsARC response at 6 months (primary - missed, p=0.06); patient global, physician global, PASI improved (secondary - significant)
Mnemonic: "MIPA - Missed It, Probably Adequate (dose failed)" M - Methotrexate | I - Inflamed joints (peripheral only) | P - PsARC (primary missed) | A - Adequate dose NOT reached (15 mg target often not achieved)
PICO 2 - SEAM-PsA Trial
P - Adults with active PsA, naive to MTX and biologics
I - Methotrexate SC 20 mg/week monotherapy (or etanercept ± MTX)
C - Etanercept 50 mg SC/week; and MTX+ETN combination
O - ACR20 at 24 weeks (primary): MTX 50.7%, ETN 60.9%, combo 65.0%
Mnemonic: "SEAM - Subcutaneous Etanercept And Methotrexate" S - SC route (higher MTX bioavailability than oral) | E - Etanercept comparator | A - ACR20 (primary) | M - MTX 20 mg/wk (higher dose, positive result)
PICO 3 - TICOPA Trial
P - Early PsA (<24 months), DMARD-naive
I - Tight control (4-weekly review, treat-to-target, escalation from MTX → combination csDMARD → bDMARD if MDA not met)
C - Standard care (review every 12 weeks, clinician discretion)
O - ACR20 at 48 weeks (primary): OR 1.91 (p=0.039); MDA 50% vs 32%; 5-year: outcomes converged
Mnemonic: "TICOPA - Tight Intervention Comparing Outcomes in Psoriatic Arthritis" T - Treat-to-target | I - Intensive (4-weekly review) | C - Csdmard backbone (MTX) | O - Outcomes improved at 1 year | P - Progressive escalation to biologic | A - Advantage lost at 5 years without continued T2T
PICO 4 - Leflunomide RCT (Kaltwasser 2004)
P - Adults with active PsA AND psoriasis (≥3% BSA), DMARD-naive
I - Leflunomide 100 mg/day loading ×3, then 20 mg/day × 24 weeks
C - Placebo
O - PsARC response at 24 weeks (primary): 58.9% vs 29.7% (p<0.0001); skin (PASI), HAQ, DLQI all improved
Mnemonic: "LEF-PsA: LEaF falling - Pyrimidine Synthesis Arrested" L - Loading dose (100 mg ×3 days) | E - Efficacy significant (p<0.0001) | F - Functions improved (HAQ, DLQI) | PsARC 59% responders | Skin benefit (PASI improved)
PICO 5 - VA Cooperative / TOPAS (Clegg 1999) - Sulfasalazine
P - Adults with peripheral OR axial seronegative spondylarthropathy (221 PsA, 264 AS, 134 ReA)
I - Sulfasalazine 2,000 mg/day
C - Placebo
O - Predefined composite response by articular type: Peripheral: SSZ 59% vs placebo 42.7% (p=0.0007); Axial: SSZ 40.2% vs placebo 43.3% (p=0.67 - no difference)
Mnemonic: "SSZ - Stops Synovitis, Zeros effect on Z-axis (axial)" S - Seronegative SpA spectrum | S - Synovitis (peripheral) - works! | Z - Zero benefit for axial disease | 2g/day dose | Reaffirmed: do NOT use SSZ for axial-predominant PsA
Overall Master Mnemonic: "SML-PAX" for csDMARDs in PsA
S - Sulfasalazine (peripheral YES, axial NO)
M - Methotrexate (peripheral maybe; no axial evidence; dose matters - SC > oral)
L - Leflunomide (strongest phase 3 evidence for peripheral; PsARC 59% positive)
P - Peripheral joints: all three csDMARDs have some RCT evidence
A - Axial PsA: NO csDMARD has evidence - use bDMARD/tsDMARD
X - eXclude hydroxychloroquine (no evidence; may exacerbate psoriasis)
Additional Quick-Reference: Endpoint Glossary for PsA Trials
| Endpoint | Description | Threshold |
|---|---|---|
| PsARC | 4-item composite (TJC, SJC, PtGA, PhGA) | Improvement ≥2/4; no worsening |
| ACR20/50/70 | Joint improvement criteria | 20%/50%/70% improvement in swollen + tender joints + 3/5 core measures |
| MDA | Minimal Disease Activity | 5/7 criteria met (TJC ≤1, SJC ≤1, PASI ≤1, VAS pain ≤15, VAS global ≤20, HAQ ≤0.5, enthesitis ≤1) |
| DAPSA | Disease Activity in PsA Score | Remission ≤4; LDA ≤14 |
| BASDAI | Bath Ankylosing Spondylitis Disease Activity Index | For axial features; ≥50% improvement or ≥2-point reduction |
| PASDAS | Psoriatic Arthritis Disease Activity Score | Composite score; MIC 0.67; MCV 1.34 |
| mSvdH | Modified Sharp/van der Heijde score | Radiographic progression measure |
Guideline Positioning (2021 GRAPPA / 2019 EULAR)
- Peripheral arthritis: csDMARD (MTX preferred; LEF/SSZ alternatives) is the standard first-line after NSAIDs fail
- Axial PsA: csDMARDs are NOT recommended - go directly to bDMARD (TNFi or IL-17i) or JAKi after NSAID failure
- Enthesitis + dactylitis: csDMARDs may help but evidence is weak; recent data suggest MTX may improve enthesitis (SEAM-PsA: 43.1% resolution)
- Skin: MTX and LEF have both joint + skin benefits; SSZ has limited skin benefit
- MTX is preferred when there is significant skin psoriasis concomitant with peripheral arthritis
Key Citations
- Wilsdon et al., Cochrane review of MTX in PsA, 2019 (PMID 30656673)
- Kaltwasser et al., Leflunomide phase 3 RCT in PsA, Arthritis Rheum 2004 (PMID 15188371)
- Clegg et al., VA Cooperative sulfasalazine in SpA, Arthritis Rheum 1999 (PMID 10555027)
- Coates et al., TICOPA - Lancet 2015 (PMID 26433318)
- James et al., TICOPA radiographic outcomes 2025 (PMID 39892892)
- Mease et al., SEAM-PsA 2022 post-hoc analysis (PMID 35428718)
- Firestein & Kelley's Textbook of Rheumatology, p.1670 - csDMARD section
- Dressler et al., Systematic review + GRADE, JEADV 2019 (PMID 30735612)
This is a shared conversation. Sign in to Orris to start your own chat.